Screener
Monopar Therapeutics MNPR Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Monopar Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The source filing: Monopar Therapeutics’s 10-Q, filed May 14, 2026.
- Filed
- May 14, 2026, 2:00 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001437749-26-016982
| Line item | For the Three Months Ended / March 31, 2026 | For the Three Months Ended / March 31, 2025 |
|---|---|---|
| In-process research and development accrued expenses | — | (3,000,000) |
| Accounts payable, accrued expenses and other current liabilities | (287,138) | (770,968) |
| Operating lease right-of-use assets and liabilities, net | (25) | (850) |
| Net cash provided by (used in) operating activities | (3,473,906) | (5,663,316) |
| Cash flows from investing activities: | ||
| Purchase of short-term investments | (40,837,552) | (1,925,828) |
| Maturities of short-term investments | 35,254,000 | 1,600,000 |
| Net cash provided by (used in) investing activities | (5,583,552) | (325,828) |
Document
FAQ
- What is Monopar Therapeutics's operating cash flow?
- Monopar Therapeutics (MNPR) reported operating cash flow of -$3.47M in Q1 2026.
- How has Monopar Therapeutics's operating cash flow changed year-over-year?
- Monopar Therapeutics's operating cash flow increased by 38.7% year-over-year, from -$5.66M to -$3.47M.
- What is the long-term trend for Monopar Therapeutics's operating cash flow?
- Over 4 years (2021 to 2025), Monopar Therapeutics's operating cash flow has grown at a 13.6% compound annual growth rate (CAGR), from -$7.32M to -$12.2M.
- What does operating cash flow mean?
- Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.
Ask your AI about Monopar Therapeutics's operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude